AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03801044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
Study NCT03801044 — intervention group
Intervention type: RADIATION
Intervention: Chest Radiography
Description: All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
Study NCT03801044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
Study NCT03801044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedence Analysis
Description: The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
Study NCT02814994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tidal volume guided by respiratory system compliance
Description: ventilated with tidal volume guided by respiratory system compliance
Study NCT02814994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low tidal volume
Description: ventilation ventilated with low tidal volume
Study NCT03645434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
Study NCT03645434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
Study NCT01798108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: - Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
Study NCT02759718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chromogranin A
Description: The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
Study NCT03180918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular tissue biopsy
Description: testicular tissue biopsy during general anesthesia
Study NCT02064582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: 160mg by mouth each day
Study NCT02064582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leuprolide acetate
Description: 22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
Study NCT02064582 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation
Description: External beam radiation will be delivered as per standard radiation therapy protocol
Study NCT01590888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBT2
Description: 250mg capsules administered orally once per day for 26 weeks
Study NCT01590888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBT2
Description: 100mg capsules administered orally once per day for 26 weeks
Study NCT01590888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally once per day for 26 weeks
Study NCT00538668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 117Lu-J591
Description: There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
Study NCT02334540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: purses
Description: food intake
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
Study NCT02334540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: a calorie/protein matched smoothie
Study NCT00879229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
Study NCT00684060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult stem cells
Description: One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
Study NCT00684060 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time infusion of 30 ml of HSA (5%)
Study NCT02331277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study NCT02331277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00696917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection 3 different vaccine lots
Study NCT00696917 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT00879229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan
Description: Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
Study NCT02052492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Study NCT00879229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan administered orally once daily.
Study NCT02085889 — intervention group
Intervention type: OTHER
Intervention: no intervention: observational study
Description: observational
Study NCT02707822 — intervention group
Intervention type: OTHER
Intervention: Clinical and genetic factors
Study NCT02310204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary education program
Description: both individual and group education sessions over a 6-month period in addition to standard psoriasis care
Study NCT02310204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard psoriasis care alone
Study NCT01574183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: up to 40 mg capsule daily
Study NCT01574183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 40 mg capsule daily
Study NCT04603027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Study NCT04603027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study NCT04669626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Ocetnilin
Description: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with Octenilin® on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with Octenilin®~* Application of new dressing (according to the wound healing phases, medical prescription)
Study NCT04669626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of NaCl 0.9%
Description: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)
Study NCT04230135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hap-pas-Hapi
Description: Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
Study NCT01069822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: IV solution
Study NCT01069822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study NCT01069822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Study NCT01227733 — intervention group
Intervention type: OTHER
Intervention: Breast Tumor Blocks
Study NCT04347707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGE Therapy Program
Description: The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
Study NCT04230135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hap-pas-Hapi
Description: Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
Study NCT00929396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
Description: o,5 mL suspension for injection x 2 with 2 months interval
Study NCT00479687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPARTZ®
Description: Three Supartz injections over 2 weeks into the glenohumeral joint space.
Study NCT00479687 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
Study NCT02841514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device
Study NCT02841514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OTC toothpaste and an unoperated Y10 device
Study NCT02064413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS310 (BAY1454032)
Study NCT03980691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chidamide with CAR-T or TCR-T cell therapy
Description: HIV-1 specific therapy
Study NCT01757249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive Pill (Microgynon 30)
Description: Pre-IVF treatment for 8 weeks
Study NCT01282619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Sustained-Release Tablet, 400µg once a day, 24 weeks
Study NCT01282619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: huperzine A
Description: Tablet, 200µg twice a day, 24 weeks
Study NCT01282619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo orally twice a day
Study NCT00498771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Exercise arm
Description: Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
Study NCT04161703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focused ultrasound, diet and exercise
Description: Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction
Study NCT04161703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diet and exercise
Description: weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A \& B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
Study NCT04415671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
Study NCT04415671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02120183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational support group therapy
Description: Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)
Study NCT00122980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red Cell Transfusions
Description: Red Blood Cell Transfusions
Study NCT00122980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iron Chelation
Description: Iron Chelation Therapy
Study NCT00122980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea
Study NCT00122980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Phlebotomy
Study NCT01437904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient Recovery
Description: Patients go home following Percutaneous nephrolithotomy
Study NCT01437904 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: In hospital recovery
Description: Patients are hospitalized following Percutaneous nephrolithotomy
Study NCT01257061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
Study NCT01257061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
Study NCT03360318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elbow cast
Description: elbow cast
Study NCT03360318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable elbow brace
Description: Removable elbow brace
Study NCT02082119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Hypofractionated IMRT
Study NCT02228837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pear
Study NCT02228837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04037696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Promotion Approach
Description: The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting.
Study NCT04037696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
Study NCT00771108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: For 16 weeks subjects will exercise from 30-60 minutes five times a week.
Study NCT00935922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Flaxseed omega-3 fatty acids and lignans
Study NCT00522431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 2% gel
Study NCT03791788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QFR assessment
Description: QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
Study NCT03924609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intensive screening / routine screening
Description: Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
Study NCT00390546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT00390546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol